Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Amazighon Jul 29, 2021 9:32am
188 Views
Post# 33620261

The slow process to success, part 2

The slow process to success, part 2
Just again a reminder for the weak hand, the pessimist, and the impatient and a summary for the patient.

The RS has been accepted. It took some time before all the legal papers/data were filed/processed/etc, but shares were eventually consolidated on the 23rd. However, this consolidation did not go so smoothly. Different brokers and banks did not consolidate shares/warrants as was intended by CLAS. Robert Farrell, I presume, was not that amused with this mess, and is probably waiting for this mess to be solved, before going ahead with his plan. I mean, would you as an investor like the SP to rise while you’re not able to buy or sell, because your broker messed up, while others can?

In the meantime, however, Robert showed us what R-107 could mean for patients with severe Covid-19 pneumonia in an NR referring to a study done by a successful and excellent institute. CLAS also granted options to directors and officers, and this is usually done in small companies for a job well done before SP will rise, in other words, a sign of good things coming our way.

Now we just have to wait until Robert thinks the mess is solved enough to start “releasing the Kraken”.

And here again, is the stuff we’re waiting for to boost the SP:

-Refund of $700,000-$900,000

-The start of phase I, and probably some other NR’s


-The private placement, and because the price is well above a certain threshold there will be institutional investors involved

-Involvement of institutional investors will drive the SP up

-Announcement of the start of the different cohorts (four in total) in phase I. The start of the next cohort means that the cohort before was successful. This of course will drive up the SP

-Because CLAS is heavily naked shorted, this will be accompanied by a nice and hopefully epic short squeeze.


SP will be well above $1 and probably even more. When phase II is finished, I cannot imagine where the price will be at that moment.

But again, this is just my opinion"


<< Previous
Bullboard Posts
Next >>